Professor Alan Boddy

Dean of Research and Institute Director UniSA Cancer Research Institute

City West Campus (HB8-26)
tel +61 8 830 22440

City East Campus (P5-06D)
tel +61 8 830 22912

email Alan.Boddy@unisa.edu.au

Alternative contact

Research Degree Supervisor

About me

After a PhD and post-doctoral training in Manchester, Alan spent a period at the University of Washington before returning to the UK to focus on cancer therapy and the role of pharmacokinetics and pharmacology more generally. In Newcastle upon Tyne he established an internationally-recognised group working on the pharmacology of drugs in early phase clinical trials, pharmacology in children with cancer and pharmacogenetics.

He was instrumental in implementing quality control standards for academic-led studies in the UK, in conjunction with Cancer Research UK and the MHRA, and led an EU-funded international study on off-patent medicines in children. Alan also founded an online MSc course in Oncology and Palliative care that provided... Read more

UniSA Cancer Research Institute

Lead cancer research with foresight, to benefit society.

Tweets by @UniversitySA

Orcid
Scopus

Research

Research themes

Cancer

Research focus

Pharmacology and Pharmaceutical Sciences
Oncology and Carcinogenesis
Biochemistry and Cell Biology
Clinical Sciences
Medical and Health Sciences

Research

Outputs

Research since 2008 is shown below. To see earlier years visit ORCID or Scopus

Open access indicates that an output is open access.

Chapters

Year	Output
2014	Jamieson, D, Coulthard, SA & Boddy, A V 2014, 'Metabolism (non-CYP enzymes)', in MA Rudek et al. (eds), Handbook of anticancer pharmacokinetics and pharmacodynamics, Springer, US, ch. 14, pp. 229-254.

Journal Articles

Year	Output
2020	Adiwidjaja, J, Boddy, A V & McLachlan, AJ 2020, 'Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics', Frontiers in Pharmacology, vol. 10, article no. 1672, pp. 1-18. Open access 4 2 1
2020	Adiwidjaja, J, Boddy, A V & McLachlan, AJ 2020, 'Physiologically-based pharmacokinetic predictions of the effect of curcumin on metabolism of imatinib and bosutinib: in vitro and in vivo disconnect', Pharmaceutical Research, vol. 37, no. 7, article no. 128, pp. 1-16. 1 1 4
2020	Adiwidjaja, J, Boddy, A V & Mclachlan, AJ 2020, 'Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach', British Journal of Clinical Pharmacology, online, pp. 1-40. Open access 1
2020	Hellmann, F, Völler, S, Krischke, M, Jamieson, D, André, N, Bisogno, G, Boddy, A & Hempel, G 2020, 'Genetic polymorphisms affecting cardiac biomarker concentrations in children with cancer: an analysis from the 'European Paediatric Oncology off-patents Medicines Consortium' (EPOC) trial', European Journal of Drug Metabolism and Pharmacokinetics, online, pp. 1-10. 1 1
2020	Liu, X, Low, SK, Atkins, JR, Wu, JQ, Reay, WR, Cairns, HM, Green, MJ, Schall, U, Jablensky, A, Mowry, B, Michie, PT, Catts, SV, Henskens, F, Pantelis, C, Loughland, C, Boddy, A V, Tooney, PA, Scott, RJ, Carr, VJ & Cairns, MJ 2020, 'Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort', Australian and New Zealand Journal of Psychiatry, vol. 54, no. 9, pp. 902-908. 1 1 2
2020	Sallustio, BS & Boddy, A V 2020, 'Is there scope for better individualisation of anthracycline cancer chemotherapy?', British Journal of Clinical Pharmacology, online, pp. 1-43.
2019	Adiwidjaja, J, Boddy, A V & McLachlan, AJ 2019, 'Physiologically based pharmacokinetic modelling of hyperforin to predict drug interactions with St John's wort', Clinical Pharmacokinetics, vol. 58, no. 7, pp. 911-926. 5 5
2019	Duong, J, Veal, G, Nath, C, Shaw, P, Errington, J, Ladenstein, R & Boddy, A 2019, 'Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function', British Journal of Clinical Pharmacology, vol 85. no 1. pp. 136-146. Open access 4 3 4
2019	Kim, HY, Upadhyay, PJ, Fahmy, A, Liu, X, Duong, JK & Boddy, A V 2019, 'Clinical pharmacokinetic and pharmacodynamic considerations in the (modern) treatment of melanoma', Clinical Pharmacokinetics, vol. 58, no. 8, pp. 1029-1043. Open access 3 3 1
2019	Shafiei, M, Yoon, R, McLachlan, A, Boddy, A, Beale, P & Blinman, P 2019, 'Pharmacokinetics of anticancer drugs used in treatment of older adults with colorectal cancer: a systematic review', Therapeutic Drug Monitoring, vol. 41, no. 5, pp. 553-560. 2 2 3
2019	Xie, J, Span, M, van Maarseveen, E, Langenhorst, J, Boddy, A V, Sia, KC, Sutton, R, Venn, N, Punt, AM, Tyrrell, V, Haber, M, Trahair, T, Lau, L, Marshall, GM & Lock, RB 2019, 'Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia', Pediatric Blood and Cancer, article no. e28133, pp. 1-10. 1
2018	Adiwidjaja, J, Boddy, A V & McLachlan, AJ 2018, 'A strategy to refine the phenotyping approach and its implementation to predict drug clearance: a physiologically‐based pharmacokinetic simulation study', CPT: Pharmacometrics and Systems Pharmacology, vol. 7, no. 12, pp. 798-808. Open access 1
2018	White-Koning, M, Osborne, C, Paci, A, Boddy, A V, Chatelut, E & Veal, GJ 2018, 'Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence', European Journal of Cancer, vol. 91, pp. 56-67. Open access 3 3 2
2017	Adiwidjaja, J, McLachlan, AJ & Boddy, A V 2017, 'Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions', Expert Opinion on Drug Metabolism and Toxicology, vol. 13, no. 9, pp. 953-972. 66 58 3
2017	Duong, JK, Griffin, MJ, Hargrave, D, Vormoor, J, Edwards, D & Boddy, A V 2017, 'A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia', British Journal of Clinical Pharmacology, vol. 83, no. 8, pp. 1713-1722. Open access 5 5
2017	Fresneau, B, Hackshaw, A, Hawkins, D, Paulussen, M, Anderson, J, Judson, I, Litiere, S, Dirksen, U, Lewis, I, van den Berg, H, Gaspar, N, Gelderblom, H, Whelan, J, Boddy, A, Wheatley, K, Pignon, J, De Vathaire, F, Le Deley, M & Le Teuff, G 2017, 'Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)', Pediatric Blood and Cancer, vol. 64, no. 8, article no. e26457, pp. 1-8. Open access 3 4 2
2017	Jamieson, D, Sunter, N, Muro, S, Pouche, L, Cresti, N, Lee, J, Sludden, J, Griffin, MJ, Allan, JM, Verrill, MW & Boddy, A V 2017, 'Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide', European Journal of Cancer, vol. 71, pp. 15-24. 6 5
2017	Kim, HY, Martin, JH, McLachlan, AJ & Boddy, A V 2017, 'Precision dosing of targeted anticancer drugs-challenges in the real world', Translational Cancer Research, vol. 6, no. S10, pp. S1500-S1511. Open access 6 7
2017	Park, JJ, Boddy, A V, Liu, X, Harris, D, Lee, V, Kefford, RF & Carlino, MS 2017, 'Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis', Pigment Cell and Melanoma Research, vol. 30, no. 1, pp. 68-71. 4 4
2017	Vormoor, B, Veal, G, Griffin, M, Boddy, A & Vormoor, J and 16 other authors 2017, 'A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia', Pediatric Blood and Cancer, vol. 64, no. 6, article no. e2635, pp. 1-4. Open access 7 8 1
2017	Völler, S, Hempel, G, Würthwein, G, Boddy, A V, Krischke, M, Andre, N, D'Incalci, M, Bisogno, G & Boos, J 2017, 'Towards a model-based dose recommendation for doxorubicin in children', Clinical Pharmacokinetics, vol. 56, no. 3, pp. 215-223. Open access 2 2
2016	Cresti, N, Lee, J, Rourke, E, Televantou, D, Jamieson, D, Verrill, M & Boddy, A V 2016, 'Genetic variants in the HER2 gene: influence on HER2 overexpression and loss of heterozygosity in breast cancer', European Journal of Cancer, vol. 55, pp. 27-37. 7 5 1
2016	Dent, BM, Ogle, LF, O'Donnell, RL, Hayes, N, Malik, U, Curtin, NJ, Boddy, A V, Plummer, R, Edmondson, RJ, Reeves, HL, May, FE & Jamieson, D 2016, 'High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers', International Journal of Cancer, vol. 138, no. 1, pp. 206-216. Open access 23 22 1
2016	Drew, Y, Ledermann, J, Hall, G, Rea, D, Glasspool, R, Highley, M, Jayson, G, Sludden, J, Murray, J, Jamieson, D, Halford, S, Acton, G, Backholer, Z, Mangano, R, Boddy, A, Curtin, N & Plummer, R 2016, 'Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer', British Journal of Cancer, vol. 114, no. 7, pp. 723-730. Open access 85 82 16
2016	Goulooze, SC, Galettis, P, Boddy, A V & Martin, JH 2016, 'Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours', Cancer Chemotherapy and Pharmacology, vol. 78, no. 1, pp. 209-216. 10 13
2016	Green, MH, Ford, JL, Green, JB, Berry, P, Boddy, A V, Oxley, A & Lietz, G 2016, 'A retinol Isotope dilution equation predicts both group and individual total body vitamin A stores in adults based on data from an early postdosing blood sample', Journal of Nutrition, vol. 146, no. 10, pp. 2137-2142. Open access 19 18 2
2016	Green, MH, Ford, JL, Oxley, A, Green, JB, Park, H, Berry, P, Boddy, A V & Lietz, G 2016, 'Plasma retinol kinetics and β-carotene bioefficacy are quantified by model-based compartmental analysis in healthy young adults with low vitamin A stores', Journal of Nutrition, vol. 146, no. 10, pp. 2129-2136. Open access 18 19 1
2016	Jamieson, D, Griffin, MJ, Sludden, J, Drew, Y, Boddy, A V & Plummer, R and 16 other authors 2016, 'A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours', European Journal of Cancer, vol. 68, pp. 1-10. Open access 4 4
2016	Krischke, M, Hempel, G, Völler, S, André, N, D'Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, A V & Boos, J 2016, 'Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial', Cancer Chemotherapy and Pharmacology, vol. 78, no. 6, pp. 1175-1184. Open access 12 12 4
2016	Liu, X, Beith, J, Low, S-K & Boddy, A V 2016, 'The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer', Pharmacogenomics, vol. 17, no. 17, pp. 1861-1864. Open access 3
2016	Liu, X, Low, SK & Boddy, A V 2016, 'The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors', Expert Opinion on Drug Metabolism and Toxicology, vol. 12, no. 8, pp. 851-863. 2 2 1
2016	Ogle, LF, Orr, JG, Willoughby, CE, Hutton, C, McPherson, S, Plummer, R, Boddy, A V, Curtin, NJ, Jamieson, D & Reeves, HL 2016, 'Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?', Journal of Hepatology, vol. 65, no. 2, pp. 305-313. 40 45 4
2016	Pu, X, Storr, SJ, Ahmad, NS, Chan, SY, Moseley, PM, Televantou, D, Cresti, N, Boddy, A V, Ellis, IO & Martin, SG 2016, 'Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study', Histopathology, vol. 68, no. 7, pp. 1021-1029. 5 4 4
2016	Veal, GJ, Cole, M, Chinnaswamy, G, Sludden, J, Jamieson, D, Errington, J, Malik, G, Hill, CR, Chamberlain, T & Boddy, A V 2016, 'Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma', European Journal of Cancer, vol. 55, pp. 56-64. Open access 21 19 2
2016	Walsh, C, Bonner, JJ, Johnson, TN, Neuhoff, S, Ghazaly, EA, Gribben, JG, Boddy, A V & Veal, GJ 2016, 'Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer', British Journal of Clinical Pharmacology, vol. 81, no. 5, pp. 989-998. Open access 14 13 1
2015	Kim, SY, Naskar, D, Kundu, SC, Bishop, DP, Doble, PA, Boddy, A V, Chan, H-K, Wall, IB & Chrzanowski, W 2015, 'Formulation of biologically-inspired silk-based drug carriers for pulmonary delivery targeted for lung cancer', Scientific Reports, vol. 5, article no. 11878, pp. 1-13. Open access 27 32 3
2015	Moreno, L, Marshall, L V, Pearson, AD, Morland, B, Elliott, M, Campbell-Hewson, Q, Makin, G, Halford, SE, Acton, G, Ross, P, Kazmi-Stokes, S, Lock, V, Rodriguez, A, Lyons, JF, Boddy, A V, Griffin, MJ, Yule, M & Hargrave, D 2015, 'A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study', Clinical Cancer Research, vol. 21, no. 2, pp. 267-273. Open access 25 26 2
2015	Parrish, KE, Cen, L, Murray, J, Calligaris, D, Kizilbash, S, Mittapalli, RK, Carlson, BL, Schroeder, MA, Sludden, J, Boddy, A V, Agar, NY, Curtin, NJ, Elmquist, WF & Sarkaria, JN 2015, 'Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts Is limited by ineffective drug penetration into the central nervous system', Molecular Cancer Therapeutics, vol. 14, no. 12, pp. 2735-2743. Open access 41 39
2015	Voeller, S, Boos, J, Krischke, M, Wuerthwein, G, Kontny, NE, Boddy, A V & Hempel, G 2015, 'Age-dependent pharmacokinetics of doxorubicin in children with cancer', Clinical Pharmacokinetics, vol. 54, no. 11, pp. 1139-1149. 13 11 1
2014	Hill, CR, Cole, M, Errington, J, Malik, G, Boddy, A V & Veal, GJ 2014, 'Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer', Clinical Pharmacokinetics, vol. 53, no. 8, pp. 741-751. Open access 24 20 1
2014	Jamieson, D, Lee, J, Cresti, N, Jackson, R, Griffin, M, Sludden, J, Verrill, M & Boddy, A V 2014, 'Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil', Cancer Chemotherapy and Pharmacology, vol. 74, no. 4, pp. 667-674. 25 25
2014	Krischke, M, Boddy, A V & Boos, J 2014, 'Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samples', Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 6, pp. 825-838. 2 2 2
2014	Murray, J, Thomas, H, Berry, P, Kyle, S, Patterson, M, Jones, C, Los, G, Hostomsky, Z, Plummer, E, Boddy, A & Curtin, N 2014, 'Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules', British Journal of Cancer, vol. 110, no. 8, pp. 1977-1984. Open access 25 25
2014	Oxley, A, Berry, P, Taylor, G, Cowell, J, Hall, MJ, Hesketh, J, Lietz, G & Boddy, A V 2014, 'An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans', Journal of Lipid Research, vol. 55, no. 2, pp. 319-328. Open access 25 25 8
2013	Boddy, A 2013, 'Genetics of cisplatin ototoxicity: Confirming the unexplained?', Clinical Pharmacology and Therapeutics, vol. 94, no. 2, pp. 198-200. 8 8
2013	Hill, CR, Jamieson, D, Thomas, HD, Brown, CD, Boddy, A V & Veal, GJ 2013, 'Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo', Biochemical Pharmacology, vol. 85, no. 1, pp. 29-37. Open access 25 26
2013	Kontny, NE, Wuerthwein, G, Boos, J, Boddy, A V, Krischke, M, Fuhr, U, Thompson, PA, Jörger, M, Schellens, JH & Hempel, G 2013, 'Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years', Cancer Chemotherapy and Pharmacology, vol. 71, no. 3, pp. 749-763. 22 22
2013	Veal, GJ, Errington, J, Rowbotham, SE, Illingworth, NA, Malik, G, Cole, M, Daly, AK, Pearson, AD & Boddy, A V 2013, 'Adaptive dosing approaches to the Individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma', Clinical Cancer Research, vol. 19, no. 2, pp. 469-479. Open access 28 23 4
2012	Jarvis, IW, Meczes, EL, Thomas, HD, Edmondson, RJ, Veal, GJ, Boddy, A V, Ottley, CJ, Pearson, DG & Tilby, MJ 2012, 'Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues', Biochemical Pharmacology, vol. 83, no. 1, pp. 69-77. 10 10
2012	Kontny, NE, Boos, J, Wuerthwein, G, Hempel, G, Boddy, A V, Groll, AH & Krischke, M 2012, 'Minimization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration', Therapeutic Drug Monitoring, vol. 34, no. 4, pp. 460-466. 5 5 2
2012	Veal, GJ & Boddy, A V 2012, 'Chemotherapy in newborns and preterm babies', Seminars in Fetal and Neonatal Medicine, vol. 17, no. 4, pp. 243-248. 17 13
2011	Chinnaswamy, G, Errington, J, Foot, A, Boddy, A V, Veal, GJ & Cole, M 2011, 'Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy', European Journal of Cancer, vol. 47, no. 10, pp. 1556-1563. 15 11
2011	Illingworth, N, Boddy, A, Daly, A & Veal, G 2011, 'Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases', British Journal of Pharmacology, vol. 162, no. 4, pp. 989-999. Open access 11 9
2011	Jamieson, D & Boddy, A V 2011, 'Pharmacogenetics of genes across the doxorubicin pathway', Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 10, pp. 1201-1210. 25 24
2011	Jamieson, D, Cresti, N, Bray, J, Sludden, J, Griffin, MJ, Hawsawi, NM, Famie, E, Mould, EV, Verrill, MW, May, FE & Boddy, A V 2011, 'Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy', Pharmacogenetics and Genomics, vol. 21, no. 12, pp. 808-819. 26 24 4
2011	Kontny, NE, Hempel, G, Boos, J, Boddy, A V & Krischke, M 2011, 'Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring: using doxorubicin as an example', Therapeutic Drug Monitoring, vol. 33, no. 6, pp. 766-771. 12 12 4
2011	Plummer, R, Wilson, R, Calvert, H, Boddy, A, Griffin, M, Sludden, J, Tilby, M, Eatock, M, Pearson, D, Ottley, C, Matsumura, Y, Kataoka, K & Nishiya, T 2011, 'A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours', British Journal of Cancer, vol. 104, no. 4, pp. 593-598. Open access 272 251 4
2011	Pridgeon, S, Heer, R, Taylor, G, Newell, D, O'Toole, K, Robinson, M, Xu, Y-Z, Karran, P & Boddy, A 2011, 'Thiothymidine combined with UVA as a potential novel therapy for bladder cancer', British Journal of Cancer, vol. 104, no. 12, pp. 1869-1876. Open access 39 36
2010	Bray, J, Sludden, J, Griffin, M, Cole, M, Verrill, M, Jamieson, D & Boddy, A 2010, 'Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide', British Journal of Cancer, vol. 102, no. 6, pp. 1003-1009. Open access 111 100
2010	Daniel, R, Rozanska, A, Mulligan, E, Drew, Y, Thomas, H, Castelbuono, D, Hostomsky, Z, Plummer, E, Tweddle, D, Boddy, A, Clifford, S & Curtin, N 2010, 'Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699', British Journal of Cancer, vol. 103, no. 9, pp. 1588-1596. Open access 38 39
2010	Israels, T, Damen, CW, Cole, M, van Geloven, N, Boddy, A V, Caron, HN, Beijnen, JH, Molyneux, EM & Veal, GJ 2010, 'Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate', European Journal of Cancer, vol. 46, no. 10, pp. 1841-1847. 21 19
2010	Rowbotham, SE, Boddy, A V, Redfern, CP, Veal, GJ & Daly, AK 2010, 'Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation', Drug Metabolism and Disposition, vol. 38, no. 8, pp. 1261-1266. 22 21
2010	Rowbotham, SE, Illingworth, NA, Daly, AK, Veal, GJ & Boddy, A V 2010, 'Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans', Drug Metabolism and Disposition, vol. 38, no. 7, pp. 1211-1217. 11 11
2009	Cruickshank, G, Ngoga, D, Detta, A, Green, S & Boddy, A and 18 other authors 2009, 'A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT', Applied Radiation and Isotopes, vol. 67, nos. 7-8, supplement, pp. S31-S33. 13 11
2009	Daniel, RA, Rozanska, AL, Thomas, HD, Mulligan, EA, Drew, Y, Castelbuono, D, Hostomsky, Z, Plummer, ER, Boddy, A V, Tweddle, DA, Curtin, NJ & Clifford, SC 2009, 'Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma', Clinical Cancer Research, vol. 15, no. 4, pp. 1241-1249. Open access 67 61
2009	Jamieson, D, Cresti, N, Verrill, MW & Boddy, A V 2009, 'Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma', Journal of Immunological Methods, vol. 345, no. 1-2, pp. 106-111. 17 18
2009	Picton, S, Keeble, J, Holden, V, Errington, J, Boddy, A & Veal, G 2009, 'Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma', Cancer Chemotherapy and Pharmacology, vol. 63, no. 4, pp. 749-752. 14 16
2009	Plummer, R, Vidal, L, Griffin, M, Lesley, M, de Bono, J, Coulthard, S, Sludden, J, Siu, LL, Chen, E X, Oza, AM, Reid, GK, McLeod, AR, Besterman, JM, Lee, C, Judson, I, Calvert, H & Boddy, A V 2009, 'Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors', Clinical Cancer Research, vol. 15, no. 9, pp. 3177-3183. Open access 77 81
2008	Chinnaswamy, G, Cole, M, Boddy, A, Keir, M, Price, L, Parry, A, English, M & Veal, G 2008, 'Estimation of renal function and its potential impact on carboplatin dosing in children with cancer', British Journal of Cancer, vol. 99, no. 6, pp. 894-899. Open access 8 8
2008	Mondick, JT, Gibiansky, L, Gastonguay, MR, Skolnik, JM, Cole, M, Veal, GJ, Boddy, A V, Adamson, PC & Barrett, JS 2008, 'Population pharmacokinetic investigation of actinomycin-D in children and young adults', Journal of Clinical Pharmacology, vol. 48, no. 1, pp. 35-42. 21 19
2008	Plummer, R, Jones, C, Middleton, M, Wilson, R, Evans, J, Olsen, A, Curtin, N, Boddy, A, McHugh, P, Newell, D, Harris, A, Johnson, P, Steinfeldt, H, Dewji, R, Wang, D, Robson, L & Calvert, H 2008, 'Phase i study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors', Clinical Cancer Research, vol. 14, no. 23, pp. 7917-7923. Open access 302 286
2008	Plummer, R, Woll, P, Fyfe, D, Boddy, A V, Griffin, M, Hewitt, P, Carmichael, J, Namouni, F, Cohen, M & Verrill, M 2008, 'A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies', Clinical Cancer Research, vol.14, no. 24, pp. 8288-8294. Open access 14 12

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Academic Medical Centre	NETHERLANDS
Aix-Marseille University	FRANCE
Alder Hey Children's NHS Foundation Trust	UNITED KINGDOM
Astex Therapeutics	UNITED STATES
Beatson West of Scotland Cancer Centre	UNITED KINGDOM
Birmingham Children's Hospital	UNITED KINGDOM
Brigham and Women's Hospital	UNITED STATES
Bristol Royal Hospital for Children	UNITED KINGDOM
Bristol-Myers Squibb, UK	UNITED STATES
Bristol-Myers Squibb, US	AUSTRALIA
Calvary Mater Hospital	AUSTRALIA
Cancer Research Uk	UNITED KINGDOM
Cantonal Hospital, St. Gallen	SWITZERLAND
Childrens Hospital of Philadelphia	UNITED STATES
Chris O'Brien Lifehouse	AUSTRALIA
CNIO	SPAIN
Concord Repatriation General Hospital	AUSTRALIA
Dankook University	KOREA, REPUBLIC OF (SOUTH)
Derriford Hospital	UNITED KINGDOM
Dipartimento di Pediatria, Padua	ITALY
Emma Children's Hospital/AMC	NETHERLANDS
EORTC Headquarters	BELGIUM
European Medicines Agency	UNITED KINGDOM
Freeman Hospital	UNITED STATES
Freeman Hospital, Newcastle-upon-Tyne Hospitals	UNITED KINGDOM
Great North Children's Hospital	UNITED KINGDOM
Great Ormond Street Hospital for Children NHS Trust	UNITED KINGDOM
Gustave Roussy	FRANCE
Gustave-Roussy	FRANCE
Hospital Timone	FRANCE
Hunter Medical Research Institute, Australia	AUSTRALIA
Indian Institute of Technology, Kharagpur	INDIA
Inserm UMR	FRANCE
Institut Gustave Roussy	FRANCE
Institute of Cancer Research	UNITED KINGDOM
Istituto di Ricerche Farmacologiche Mario Negri	ITALY
Leeds General Infirmary	UNITED KINGDOM
Leiden Academic Centre for Drug Research	NETHERLANDS
Leiden University	NETHERLANDS
Mayo Clinic	UNITED STATES
Melanoma Institute Australia	AUSTRALIA
Merck Research Laboratories	UNITED STATES
MethylGene	CANADA
Metrum Institute	UNITED STATES
NanoCarrier	JAPAN
National Cancer Center Hospital East	UNITED STATES
Netherlands Cancer Institute	NETHERLANDS
Newcastle Freeman Hospital	UNITED KINGDOM
Newcastle University, United Kingdom	UNITED KINGDOM
Newcastle upon Tyne Hospitals NHS Foundation Trust	UNITED KINGDOM
Northern Centre for Cancer Care	UNITED KINGDOM
Northern Centre for Cancer Care, Freeman Hospital	UNITED KINGDOM
Northern Institute for Cancer Research	UNITED KINGDOM
Nottingham City Hospital	UNITED KINGDOM
Nottingham University Hospitals NHS Trust	UNITED KINGDOM
Paul Sabatier University	FRANCE
Pennsylvania State University	UNITED STATES
Pfizer Australia Pty Ltd	AUSTRALIA
Pfizer Global Research and Development	UNITED STATES
Pfizer Limited, UK	UNITED KINGDOM
Pfizer Oncology	UNITED STATES
Princess Margaret Hospital	TUVALU
Queen Mary University of London	UNITED KINGDOM
Queen's University Belfast	UNITED KINGDOM
Royal Marsden Hospital	UNITED KINGDOM
Royal Victoria Infirmary	UNITED KINGDOM
Saint Anna Children's Hospital	AUSTRIA
Simcyp Limited (a Certara Company)	UNITED KINGDOM
St James's University Hospital	UNITED KINGDOM
St. James's Hospital	UNITED STATES
Tata Memorial Hospital	INDIA
Texas Children's Cancer center	UNITED STATES
The Royal Marsden NHS Foundation Trust	UNITED KINGDOM
UCL Cancer Institute	UNITED KINGDOM
UniversitÃ© Paris-Saclay	FRANCE
University College Hospital	UNITED KINGDOM
University College London	UNITED KINGDOM
University Hospital Muenster	GERMANY
University Institute Cancer Toulouse Oncopole	FRANCE
University of Adelaide	AUSTRALIA
University of Birmingham	UNITED KINGDOM
University of Cologne	GERMANY
University of Durham	UNITED KINGDOM
University of Glasgow	UNITED KINGDOM
University of Malawi	MALAWI
University of Manchester	UNITED KINGDOM
University of Melbourne	AUSTRALIA
University of Minnesota, Twin Cities	UNITED STATES
University of Muenster	GERMANY
University of New South Wales	AUSTRALIA
University of Newcastle	AUSTRALIA
University of Nottingham	UNITED KINGDOM
University of Oxford	UNITED KINGDOM
University of Padova	ITALY
University of Queensland	AUSTRALIA
University of South Australia	AUSTRALIA
University of Sydney	AUSTRALIA
University of Technology Sydney	AUSTRALIA
University of Tokyo	JAPAN
University of Washington	UNITED STATES
University of Western Australia	AUSTRALIA
Utrecht University	NETHERLANDS
Westfälische Wilhelms-Universität Münster	GERMANY
Westmead Hospital	AUSTRALIA
Witten/Herdecke University	GERMANY

External engagement & recognition

Engagement/recognition	Year
Editorial Board Member Cancer Chemotherapy and Pharmacology	2018
Executive Editor British Journal of Clinical Pharmacology	2018
Member Pharmacokinetics, United Kingdom	2018
Member British Association for Cancer Research	2018
Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)	2018
Editorial Board Member Cancer Chemotherapy and Pharmacology	2017
Executive Editor British Journal of Clinical Pharmacology	2017
Founding member, Experimental Cancer Medicine Quality Assurance group Cancer Research, Department of Health, United Kingdom	2017
Member Pharmacokinetics, United Kingdom	2017
Member British Association for Cancer Research	2017
Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)	2017
Member, Pharmacogenetics Interest Group Australian Society of Clinical and Experimental Pharmacology and Therapeutics	2017
Editorial Board Member Cancer Chemotherapy and Pharmacology	2016
Executive Editor British Journal of Clinical Pharmacology	2016
Member Pharmacokinetics, United Kingdom	2016
Member British Association for Cancer Research	2016
Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)	2016
Editorial Board Member Cancer Chemotherapy and Pharmacology	2015
Executive Editor British Journal of Clinical Pharmacology	2015
Member Pharmacokinetics, United Kingdom	2015
Member British Association for Cancer Research	2015
Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)	2015
Editorial Board Member Clinical Pharmacokinetics	2014
Editorial Board Member Cancer Chemotherapy and Pharmacology	2014
Executive Editor British Journal of Clinical Pharmacology	2014
Member Pharmacokinetics, United Kingdom	2014
Member British Association for Cancer Research	2014
Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)	2014
Member, New Agents Group National Cancer Research Institute, United Kingdom	2014
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2014
Member, Phase I Clinical Trials Group Newcastle University/Trust	2014
Editorial Board Member Clinical Pharmacokinetics	2013
Editorial Board Member Cancer Chemotherapy and Pharmacology	2013
Executive Editor British Journal of Clinical Pharmacology	2013
Member Language Resources and Evaluation (LREC), Newcastle and North Tyneside	2013
Member Pharmacokinetics, United Kingdom	2013
Member British Association for Cancer Research	2013
Member, New Agents Group National Cancer Research Institute, United Kingdom	2013
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2013
Member, Phase I Clinical Trials Group Newcastle University/Trust	2013
Editorial Board Member Clinical Pharmacokinetics	2012
Editorial Board Member Cancer Chemotherapy and Pharmacology	2012
Executive Editor British Journal of Clinical Pharmacology	2012
Member Language Resources and Evaluation (LREC), Newcastle and North Tyneside	2012
Member Pharmacokinetics, United Kingdom	2012
Member British Association for Cancer Research	2012
Member, New Agents Group National Cancer Research Institute, United Kingdom	2012
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2012
Member, Phase I Clinical Trials Group Newcastle University/Trust	2012
Editorial Board Member Clinical Pharmacokinetics	2011
Editorial Board Member Cancer Chemotherapy and Pharmacology	2011
Executive Editor British Journal of Clinical Pharmacology	2011
Member Language Resources and Evaluation (LREC), Newcastle and North Tyneside	2011
Member Pharmacokinetics, United Kingdom	2011
Member British Association for Cancer Research	2011
Member, New Agents Group National Cancer Research Institute, United Kingdom	2011
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2011
Member, Phase I Clinical Trials Group Newcastle University/Trust	2011
Editorial Board Member Clinical Pharmacokinetics	2010
Editorial Board Member Cancer Chemotherapy and Pharmacology	2010
Member Language Resources and Evaluation (LREC), Newcastle and North Tyneside	2010
Member Pharmacokinetics, United Kingdom	2010
Member British Association for Cancer Research	2010
Member, New Agents Group National Cancer Research Institute, United Kingdom	2010
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2010
Member, Phase I Clinical Trials Group Newcastle University/Trust	2010
Editorial Board Member Clinical Pharmacokinetics	2009
Editorial Board Member Cancer Chemotherapy and Pharmacology	2009
Member Language Resources and Evaluation (LREC), Newcastle and North Tyneside	2009
Member Pharmacokinetics, United Kingdom	2009
Member British Association for Cancer Research	2009
Member American Association for Cancer Research	2009
Member, New Agents Group National Cancer Research Institute, United Kingdom	2009
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2009
Member, Phase I Clinical Trials Group Newcastle University/Trust	2009
Editorial Board Member Clinical Pharmacokinetics	2008
Editorial Board Member Cancer Chemotherapy and Pharmacology	2008
Member Language Resources and Evaluation (LREC), Newcastle and North Tyneside	2008
Member Pharmacokinetics, United Kingdom	2008
Member British Association for Cancer Research	2008
Member American Association for Cancer Research	2008
Member, New Agents Group National Cancer Research Institute, United Kingdom	2008
Member, Pharmacology and Molecular Mechanisms group European Organisation for Research and Treatment of Cancer (EORTC)	2008
Member, Phase I Clinical Trials Group Newcastle University/Trust	2008

more less

Professor Alan Boddy

Alternative contact

Alternative contact details

About me

About me

UniSA Cancer Research Institute

About me

Professional Associations

Experience

Qualifications

Research

Research themes

Research focus

Projects

Outputs

Chapters

Journal Articles

External engagement & recognition

Collaborations

Collaborations

External engagement & recognition

Editorial Board Member

Executive Editor

Member

Member

Member

Editorial Board Member

Executive Editor

Founding member, Experimental Cancer Medicine Quality Assurance group

Member

Member

Member

Member, Pharmacogenetics Interest Group

Editorial Board Member

Executive Editor

Member

Member

Member

Editorial Board Member

Executive Editor

Member

Member

Member

Editorial Board Member

Editorial Board Member

Executive Editor

Member

Member

Member

Member, New Agents Group

Member, Pharmacology and Molecular Mechanisms group

Member, Phase I Clinical Trials Group

Editorial Board Member

Editorial Board Member

Executive Editor

Member

Member

Member

Member, New Agents Group

Member, Pharmacology and Molecular Mechanisms group

Member, Phase I Clinical Trials Group

Editorial Board Member

Editorial Board Member

Executive Editor

Member

Member

Member

Member, New Agents Group

Member, Pharmacology and Molecular Mechanisms group

Member, Phase I Clinical Trials Group

Editorial Board Member

Editorial Board Member

Executive Editor

Member

Member

Member

Member, New Agents Group

Member, Pharmacology and Molecular Mechanisms group

Member, Phase I Clinical Trials Group

Editorial Board Member